Wilms tumour (WT) patients with a localised completely necrotic nephroblastoma after preoperative chemotherapy are a favourable outcome group. Since the introduction of the SIOP 2001 protocol, the SIOP- Renal Tumour Study Group (SIOP-RTSG) has omitted radiotherapy for such patients with low-risk, local stage III in an attempt to reduce treatment burden. However, for metastatic patients with local stage III, completely necrotic WT, the recommendations led to ambiguous use. The purpose of this descriptive study is to demonstrate the outcomes of patients with metastatic, completely necrotic and local stage III WT in relation to the application of radiotherapy or not. all metastatic patients with local stage III, completely necrotic WT after 6 ...
Background: As a significant proportion of relapses occurred in the tumor bed or abdomen on patients...
In the SIOP Wilms' tumor (WT) studies, preoperative chemotherapy is used as primary treatment, and t...
Purpose: The SIOP WT 2001 trial introduced a new ‘high risk’ entity: ‘blastemal type’ WT. However, t...
International audienceObjective: Wilms tumour (WT) patients with a localised completely necrotic nep...
High-risk (HR) metastatic (stage IV) Wilms tumours (WTs) have a particular poor outcome. Here, we re...
Introduction: High-risk (HR) metastatic (stage IV) Wilms tumours (WTs) have a particular poor outcom...
Blastemal-type Wilms tumour (BT-WT) has been identified as a high risk histological subgroup in WT a...
In SIOP trials, Wilms' tumors were labeled as stage II by the presence of nonviable and/or viable tu...
The randomised findings of the UKW3 trial were that preoperative chemotherapy was associated with a ...
The SIOP nephroblastoma clinical trials have previously demonstrated that preoperative chemotherapy ...
BACKGROUND AND PURPOSE: To describe the outcome of patients with stage III Wilms tumours (WT) treat...
The Sixth International Society of Pediatric Oncology study (SIOP6) concerned Wilms' tumor with favo...
As a significant proportion of relapses occurred in the tumor bed or abdomen on patients with the fi...
Objective: To evaluate the value of radiotherapy boost omission in patients with intermediate-risk, ...
Objective: To evaluate the value of radiotherapy boost omission in patients with intermediate-risk, ...
Background: As a significant proportion of relapses occurred in the tumor bed or abdomen on patients...
In the SIOP Wilms' tumor (WT) studies, preoperative chemotherapy is used as primary treatment, and t...
Purpose: The SIOP WT 2001 trial introduced a new ‘high risk’ entity: ‘blastemal type’ WT. However, t...
International audienceObjective: Wilms tumour (WT) patients with a localised completely necrotic nep...
High-risk (HR) metastatic (stage IV) Wilms tumours (WTs) have a particular poor outcome. Here, we re...
Introduction: High-risk (HR) metastatic (stage IV) Wilms tumours (WTs) have a particular poor outcom...
Blastemal-type Wilms tumour (BT-WT) has been identified as a high risk histological subgroup in WT a...
In SIOP trials, Wilms' tumors were labeled as stage II by the presence of nonviable and/or viable tu...
The randomised findings of the UKW3 trial were that preoperative chemotherapy was associated with a ...
The SIOP nephroblastoma clinical trials have previously demonstrated that preoperative chemotherapy ...
BACKGROUND AND PURPOSE: To describe the outcome of patients with stage III Wilms tumours (WT) treat...
The Sixth International Society of Pediatric Oncology study (SIOP6) concerned Wilms' tumor with favo...
As a significant proportion of relapses occurred in the tumor bed or abdomen on patients with the fi...
Objective: To evaluate the value of radiotherapy boost omission in patients with intermediate-risk, ...
Objective: To evaluate the value of radiotherapy boost omission in patients with intermediate-risk, ...
Background: As a significant proportion of relapses occurred in the tumor bed or abdomen on patients...
In the SIOP Wilms' tumor (WT) studies, preoperative chemotherapy is used as primary treatment, and t...
Purpose: The SIOP WT 2001 trial introduced a new ‘high risk’ entity: ‘blastemal type’ WT. However, t...